United States Attorney's Office for the District of Nevada

09/16/2025 | Press release | Distributed by Public on 09/16/2025 17:18

Henderson Man Indicted For Illegal Smuggling And Distribution Of Erectile Dysfunction Prescription Drugs Under Brand Names 'Kinky Kong,' 'Kinky Pink,' 'Stif,' Tbone,' And 'Ride'

Press Release

Henderson Man Indicted For Illegal Smuggling And Distribution Of Erectile Dysfunction Prescription Drugs Under Brand Names "Kinky Kong," "Kinky Pink," "Stif," Tbone," And "Ride"

Tuesday, September 16, 2025
Share
  • Facebook
  • X
  • LinkedIn
  • Email
For Immediate Release
U.S. Attorney's Office, District of Nevada
The Defendant Allegedly Made Over $2.5 Million in Revenue From the Sales of Misbranded Prescription Drugs

LAS VEGAS - A Henderson, Nevada, resident made his initial appearance in court on September 10, 2025, to face charges for allegedly smuggling misbranded prescription drugs containing sildenafil and tadalafil, the active ingredients in FDA-approved prescription drugs Viagra and Cialis, into the United States. According to allegations in the indictment, David Ralph Webber then sold the drugs to smoke shops, convenience stores, and adult novelty stores, as well as directly to consumers through his website, under brand names "Kinky Kong," "Kinky Pink," "Stif," "Tbone," and "Ride."

"Americans depend on the FDA to ensure that drugs are safe and accurately labeled," said FDA Special Agent in Charge Robert M. Iwanicki of the FDA's Office of Criminal Investigations Los Angeles Field Office. "Today's announcement illustrates our ongoing emphasis on holding accountable people who circumvent federal regulations and jeopardize public health."

A federal grand jury indicted Webber on July 30, 2025, with one count of introduction of a misbranded drug into interstate commerce, four counts of wholesale distribution of prescription drugs without a license, and seven counts of smuggling.

According to allegations contained in court documents and statements made in court, Webber owned and operated two Nevada companies: Passion Plus Enterprises Inc. and Whole Science Health. He was not a registered pharmaceutical manufacturer with the FDA, nor was he licensed to administer prescription drugs or as a wholesaler of prescription drugs.

As alleged, from at least 2018 to present, Webber purchased hundreds of thousands of capsules containing sildenafil and tadalafil-the active ingredients in Viagra and Cialis-from manufacturers in India. Once Webber received the products, he allegedly distributed them in Nevada and throughout the southwestern United States, including to third-party stores and directly to consumers. According to allegations contained in the indictment, these products have potentially harmful effects if not properly administered by a licensed practitioner. This is particularly true for persons on heart and/or blood-thinning medications.

As part of the scheme, Webber allegedly paid a packaging company to list false ingredients and false claims that the drugs were "100% Natural" and did not require a prescription. It is alleged that many, if not most, consumers were not aware they were taking prescription medicines containing the same active ingredients as Viagra and Cialis.

A jury trial is set for November 18, 2025, before United States District Judge Jennifer A. Dorsey.

Acting United States Attorney Sigal Chattah for the District of Nevada and Special Agent in Charge Robert M. Iwanicki of the FDA's Office of Criminal Investigations Los Angeles Field Office made the announcement.

This case was investigated by the FDA and United States Postal Inspection Service. Assistant United States Attorney Jean Ripley is prosecuting the case.

If you or someone you know has taken these products and/or suffered adverse health effects as a result of these products, please contact investigators at https://www.accessdata.fda.gov/scripts/email/oc/oci/contact.cfm.

An indictment is merely an accusation, and a defendant is presumed innocent unless and until proven guilty.

###

Updated September 16, 2025
Topic
Prescription Drugs
Component
USAO - Nevada
United States Attorney's Office for the District of Nevada published this content on September 16, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 16, 2025 at 23:18 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]